James Brown, MD
Pulmonary Disease · Lakeland, FLNPI 1538456439
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (35.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Boehringer Ingelheim at 38.7% of the total. Reporting peaked in 2024 at $17,508 and has fallen 95.6% since, to $763 in 2025.
Across 69 payments — averaging $340.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$9K
- United Therapeutics Corporation$9K
- Grifols USA, LLC$3K
- Olympus Corporation Of The Americas$996
- Actelion Pharmaceuticals US, Inc.$604
- AstraZeneca$450
- plus $490 from 6 others
Across 19 payments — averaging $8897.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$93K
- United Therapeutics Corporation$76K
What the payments were for
- Consulting fees$8,28535%
- Speaking & faculty fees$6,77029%
- Travel & lodging$4,55619%
- Food & beverage$3,74316%
- Education$1201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 8 | $9,074 |
| United Therapeutics Corporation | 27 | $8,960 |
| Grifols USA, LLC | 4 | $2,901 |
| Olympus Corporation Of The Americas | 8 | $996 |
| Actelion Pharmaceuticals US, Inc. | 7 | $604 |
| AstraZeneca | 6 | $450 |
| GSK | 4 | $230 |
| Johnson & Johnson | 1 | $120 |
| BD | 1 | $92 |
| Bayer | 1 | $18 |
| CSL Behring | 1 | $17 |
| Electromed, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,474 in reported general payments places this provider in the 85th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 46 | $617,302 |
| Tyvaso DpiTreprostinil | 20 | $424,266 |
| OpsumitMacitentan | 22 | $278,784 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 292 | $232,946 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 14 | $214,660 |
| Fasenra PenBenralizumab | 29 | $169,978 |
| Dupixent PenDupilumab | 38 | $154,226 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 185 | $140,840 |
| AdempasRiociguat | 11 | $132,427 |
| NucalaMepolizumab | 27 | $112,439 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 119 | $74,481 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 128 | $65,355 |
| Pirfenidone | 36 | $52,188 |
| Varenicline Tartrate | 201 | $49,745 |
| Spiriva RespimatTiotropium Bromide | 50 | $35,724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $9,074 | $747,549247 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $230 | $445,153535 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $604 | $278,78422 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $450 | $184,743295 claims |
| BayerAdempas | $18 | $132,42711 claims |
| Johnson & JohnsonXarelto | $120 | $6,37112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Lakeland
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.